^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

pegylated irinotecan (SSS22)

i
Associations
Trials
Company:
3SBio, JenKem Technology
Drug class:
Topoisomerase I inhibitor
Related drugs:
Associations
Trials
5ms
New P3 trial
|
topotecan • pegylated irinotecan (SSS22)
7ms
New P2 trial • Surgery
|
temozolomide • pegylated irinotecan (SSS22)
7ms
New P2 trial
|
pegylated irinotecan (SSS22)
8ms
New P3 trial
|
topotecan • pegylated irinotecan (SSS22)
over1year
Full-profile pharmacokinetics, anticancer activity and toxicity of an extended release trivalent PEGylated irinotecan prodrug. (PubMed, Acta Pharm Sin B)
In summary, PEG-[Irinotecan] displays superior pharmacokinetic characteristics and antitumor activity with lower toxicity than irinotecan. This supports the view that PEG-[Irinotecan] is a superior anticancer drug to irinotecan and it has entered the phase II trial stage.
PK/PD data • Journal
|
irinotecan • Onzeald (etirinotecan pegol) • pegylated irinotecan (SSS22)